v3.25.2
Acquisitions (Details)
$ in Thousands, SFr in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 19, 2023
USD ($)
Oct. 31, 2025
CHF (SFr)
Jan. 31, 2025
USD ($)
Jan. 31, 2025
CHF (SFr)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2023
CHF (SFr)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
CHF (SFr)
Sep. 30, 2022
CHF (SFr)
Business Combination [Line Items]                      
Equity securities without readily determinable fair value, amount                     SFr 8.0
Acquired in-process research and development expenses | $         $ 0 $ 0   $ 75,217 $ 0    
AMF Medical Acquisition                      
Business Combination [Line Items]                      
Payments of cash       SFr 68.0     SFr 62.4        
Additional earnout payment             SFr 129.6        
Price of acquisition, expected       SFr 40.0              
Acquired in-process research and development expenses | $ $ 78,800   $ 68,000                
Remaining short-term accrued liability         $ 35,200     $ 35,200   SFr 28.0  
AMF Medical Acquisition | Forecast                      
Business Combination [Line Items]                      
Price of acquisition, expected   SFr 28.0